Shaperon Inc. (KOSDAQ:378800)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,679.00
-129.00 (-7.13%)
At close: Mar 9, 2026
-48.18%
Market Cap 77.64B
Revenue (ttm) 179.38M
Net Income (ttm) -14.59B
Shares Out 46.24M
EPS (ttm) -541.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 728,852
Average Volume 984,331
Open 1,700.00
Previous Close 1,808.00
Day's Range 1,618.00 - 1,757.00
52-Week Range 1,523.00 - 4,020.00
Beta 0.12
RSI 46.74
Earnings Date Nov 14, 2025

About Shaperon

Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata. The company also provides NuCerin, a pill designed to reduce neuroinflammation; NuSepin, which alleviates excessive systemic inflammation; and NuP... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 378800
Full Company Profile

Financial Performance

In 2024, Shaperon's revenue was 17.70 million, a decrease of -91.77% compared to the previous year's 215.25 million. Losses were -14.90 billion, 20.2% more than in 2023.

Financial Statements

News

There is no news available yet.